이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Amphastar Pharmaceuticals 관리
관리 기준 확인 3/4
Amphastar Pharmaceuticals' CEO는 Jack Zhang, Jan1996 에 임명되었습니다 의 임기는 28.42 년입니다. 총 연간 보상은 $ 7.72M, 11.6% 로 구성됩니다. 11.6% 급여 및 88.4% 보너스(회사 주식 및 옵션 포함). 는 $ 93.63M 가치에 해당하는 회사 주식의 4.78% 직접 소유합니다. 93.63M. 경영진과 이사회의 평균 재임 기간은 각각 10.6 년과 5 년입니다.
주요 정보
Jack Zhang
최고 경영자
US$7.7m
총 보상
| CEO 급여 비율 | 11.6% |
| CEO 임기 | 28.5yrs |
| CEO 소유권 | 4.8% |
| 경영진 평균 재임 기간 | 10.7yrs |
| 이사회 평균 재임 기간 | 5.1yrs |
최근 관리 업데이트
Recent updates
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Feb 13CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$6m | US$880k | US$4m |
보상 대 시장: Jack 의 총 보상 ($USD 7.72M )은 US 시장( $USD 5.67M ).
보상과 수익: Jack 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Jack Zhang (77 yo)
28.5yrs
테뉴어
US$7,722,768
보상
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman of the Board | 28.5yrs | US$3.77m | 2.34% $ 44.2m | |
| Co-founder | 28.5yrs | US$7.72m | 4.78% $ 90.2m | |
| CFO, Executive VP of Finance | 10.3yrs | US$2.89m | 0.081% $ 1.5m | |
| Executive VP of Sales | 11.1yrs | US$1.78m | 0.095% $ 1.8m | |
| Senior EVP of Production & EVP of Scientific Affairs | 9.1yrs | US$2.03m | 0.38% $ 7.2m | |
| Senior Vice President of Human Resources & Corporate Communication | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | 데이터 없음 | 데이터 없음 |
10.7yrs
평균 재임 기간
65yo
평균 연령
경험이 풍부한 관리: AMPH 의 관리팀은 노련하고 경험 (평균 재직 기간 10.6 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman of the Board | 28.5yrs | US$3.77m | 2.34% $ 44.2m | |
| Co-founder | 28.5yrs | US$7.72m | 4.78% $ 90.2m | |
| CFO, Executive VP of Finance | 1.9yrs | US$2.89m | 0.081% $ 1.5m | |
| Executive VP of Sales | 1.9yrs | US$1.78m | 0.095% $ 1.8m | |
| Lead Independent Director | 22.4yrs | US$362.00k | 0.058% $ 1.1m | |
| Independent Director | 3.1yrs | US$330.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.1yrs | US$314.70k | 0.026% $ 495.2k |
5.1yrs
평균 재임 기간
65.5yo
평균 연령
경험이 풍부한 이사회: AMPH 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.